AMS is a nuclear medicine start-up executing new business and economic growth opportunities in Japan and the Asian region based on next-generation targeted radiopharmaceuticals. We are in-process of bringing a new prostate cancer diagnostic capability to the Japanese market in addition to working on the treatment side. There are two market trends driving AMS’ strategic growth plan: (1) the March 2011 Nuclear Power Station Accident in Japan, and (2) the Japanese phase-out of Russian radioisotope imports starting in 2022. Since February 2020, utilizing approximately $1.5M in funding, AMS has built a talented team of medical, technical and business experts to progress pre-clinical R&D in preparation for Phase 1 clinical trial of 68Ga PSMA-11 PET in Recurrent Prostate Cancer scheduled in 1Q 2023. AMS seeks to raise $10M for Phase 2 and will execute bridging studies in the United States to omit Phase 3 clinical trial, reducing PMDA approval timelines and accelerating our time to market.
In addition, AMS is partnering with several well-known Japanese medical institutes to develop actinium225 (Ac225) bearing cancer treatment drugs based upon a proprietary research and development plan. AMS also seeks to raise $10M to expand our business to secure long-term, stable supplies of vital medical isotopes, including Ac225 from the U.S., and seed funds for developing new treatments with Japanese research institutions and hospitals.